10-Q: Anavex Reports Q3 2025 Loss, Advances Clinical Pipeline

Anavex Life Sciences Corp. reported an increased net loss for Q3 2025, alongside significant progress in its Alzheimer's and schizophrenia clinical programs and new capital raising initiatives.

Summary

• Net loss for the three months ended June 30, 2025, was $13.2 million, or $0.16 per share, compared to $12.2 million, or $0.14 per share, for the same period in fiscal 2024.
• Net loss for the nine months ended June 30, 2025, was $36.6 million, or $0.43 per share, compared to $31.4 million, or $0.38 per share, for the nine months ended June 30, 2024.
• Cash and cash equivalents decreased to $101.164 million as of June 30, 2025, from $132.187 million as of September 30, 2024.
• Research and development expenses decreased to $10.0 million for the three months ended June 30, 2025, from $11.8 million in the prior year, primarily due to completion of a large manufacturing campaign for ANAVEX2-73 and the Alzheimer's program's open label extension.
• Research and development expenses for the nine months ended June 30, 2025, were consistent at $30.3 million, compared to $30.2 million in the prior year, with increased spending on ANAVEX3-71-SZ-001 clinical trial offset by decreases in Alzheimer's program and manufacturing activities.
• General and administrative expenses increased to $4.5 million for the three months ended June 30, 2025, from $2.8 million in the prior year, and to $10.3 million for the nine months ended June 30, 2025, from $8.4 million in the prior year, mainly due to corporate and intellectual property legal fees and increased share-based compensation.
• Net other income decreased to $1.2 million for the three months ended June 30, 2025, from $2.4 million in the prior year, and to $4.0 million for the nine months ended June 30, 2025, from $7.2 million in the prior year, due to decreased R&D incentive income and lower interest income.
• A Marketing Authorisation Application (MAA) for ANAVEX2-73 for Alzheimer's disease was submitted to the European Medicines Agency (EMA) in November 2024 and accepted for scientific review in December 2024.
• Enrollment for Part B of the ANAVEX3-71-SZ-001 Phase 2 study in schizophrenia was completed in May 2025.
• A new Sales Agreement was entered into with TD Securities (USA) LLC on July 25, 2025, to offer and sell up to $150 million in common stock through an at-the-market offering.
• An unused amount of $110.8 million remains under the 2023 Purchase Agreement with Lincoln Park Capital Fund, LLC, which expires on February 3, 2026, requiring a prospectus supplement to access funds.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While financial results show increased losses and cash burn, which are negative, the significant clinical progress, particularly the EMA MAA acceptance for Alzheimer's and the completion of enrollment for the schizophrenia trial, are strong positive catalysts. The new capital raise facility provides financial flexibility. The ongoing legal challenges are a concern, but the dismissal of the class action lawsuit (despite appeal) mitigates some immediate risk. The mixed results for the Rett syndrome trial are a slight dampener but not a complete failure.

Positives

• Submission of Marketing Authorisation Application (MAA) for ANAVEX2-73 for Alzheimer's disease to the European Medicines Agency (EMA) in November 2024, which was accepted for scientific review in December 2024, represents a significant regulatory milestone.
• The long-term open label extension study (ATTENTION-AD trial) for ANAVEX2-73 in Alzheimer's disease, completed in June 2024, demonstrated continued patient benefit for up to 4 years and confirmed a good comparative safety profile with no new safety findings.
• Completion of enrollment for Part B of the ANAVEX3-71-SZ-001 Phase 2 study in schizophrenia in May 2025 indicates progress in this clinical program.
• Preliminary results from Part A of the ANAVEX3-71-SZ-001 clinical trial showed a dose-dependent effect on key EEG biomarkers in schizophrenia patients, reversing known abnormalities.
• The EXCELLENCE trial (pediatric Rett syndrome) showed improvement on the RSBQ co-primary endpoint and a rapid onset of action at 4 weeks, with no new safety signals.
• High enrollment (over 91%) in the Open Label Extension (OLE) and high requests (93%) for the Compassionate Use Program for Rett syndrome patients suggest positive real-world evidence and patient/caregiver satisfaction.
• The company maintains a strong working capital position of $90.958 million as of June 30, 2025, which management believes is sufficient to meet working capital requirements beyond the next 12 months.
• The new Sales Agreement with TD Securities provides access to up to $150 million in additional capital, enhancing financial flexibility.

Negatives

• Net loss increased to $13.2 million for the three months ended June 30, 2025, from $12.2 million in the comparable prior period, and to $36.6 million for the nine months ended June 30, 2025, from $31.4 million in the comparable prior period.
• Cash and cash equivalents decreased by approximately $31.023 million during the nine months ended June 30, 2025, primarily due to cash used in operating activities.
• Net cash used in operating activities increased to $30.4 million for the nine months ended June 30, 2025, from $24.2 million in the comparable prior period.
• Net other income decreased significantly due to a reduction in research and development incentive income (from Australian clinical trials completion) and lower interest income.
• The EXCELLENCE trial for pediatric Rett syndrome did not meet its other co-primary endpoint, Clinical Global Impression – Improvement (CGI-I).
• Ongoing legal proceedings, including a shareholder class action lawsuit (dismissed but appealed) and two derivative lawsuits, pose a potential financial and reputational burden, even if the company believes no loss is probable.

Risks

• The marketing approval process for pharmaceutical products is lengthy, complex, highly regulated, and inherently unpredictable, with no guarantee of marketing approval.
• Regulatory authorities (EMA, FDA) may impose evolving requirements, including additional clinical trials, or delay/refuse approval, potentially finding the Phase 2b/3 ANAVEX2-73-AD-004 clinical trial insufficient to support marketing authorization.
• Obtaining regulatory approval in one jurisdiction does not guarantee approval in others, and failure or delay in one jurisdiction may negatively affect processes in others.
• The company has not generated any revenue from operations to date and expects to continue experiencing negative cash flows for the foreseeable future, with no certainty of becoming profitable.
• There is no assurance that additional financing will be available when needed or on commercially reasonable terms, beyond existing agreements, which could force delays or scaling down of research and development activities.
• The company is subject to claims and legal proceedings that arise in the ordinary course of business, which are inherently uncertain and could have a material adverse effect on financial statements or require significant resources.
• Changes in U.S. and international trade policies, such as tariffs, could adversely impact business and operating results by affecting import/export costs or demand for product candidates.

Future Outlook

The company anticipates conducting further clinical trials of ANAVEX2-73 in Parkinson's disease dementia after submitting trial results to regulatory authorities for guidance. Top-line data for the Phase 2 ANAVEX3-71-SZ-001 clinical trial in schizophrenia is expected in the second half of 2025. The company continues to identify and initiate discussions with potential strategic and commercial partners to advance programs and increase stockholder value, and may acquire or develop new intellectual property. Management believes current working capital will be sufficient to meet requirements beyond the next 12 months, but acknowledges the need for additional financing if and when required, which may involve filing a prospectus supplement for the 2023 Purchase Agreement or utilizing the new Sales Agreement.

Management Comments

• Management believes that the current working capital position will be sufficient to meet the company's working capital requirements beyond the next 12 months after the date that these condensed consolidated interim financial statements are issued.
• The process of drug development can be costly, and the timing and outcomes of clinical trials are uncertain.
• The company has the ability to adjust its operating plan spending levels based on the timing of future clinical trials.
• We anticipate conducting further clinical trials of ANAVEX2-73 in Parkinson's disease dementia after submitting the results of the trial to regulatory authorities to obtain regulatory guidance.
• We expect to report top-line data of the Phase 2 ANAVEX3-71-SZ-001 clinical trial in the second half of 2025.
• We continue to identify and initiate discussions with potential strategic and commercial partners to most effectively advance our programs and increase stockholder value.
• We may acquire or develop new intellectual property and assign, license, or otherwise transfer our intellectual property to further our goals.

Industry Context

Anavex operates in the highly competitive and rapidly evolving biopharmaceutical sector, specifically targeting central nervous system (CNS) diseases with high unmet needs such as Alzheimer's, Parkinson's, Rett syndrome, and schizophrenia. The company's precision medicine approach, focusing on genomic data and biomarkers like SIGMAR1, aligns with a growing industry trend towards personalized therapeutics. The ongoing challenges in developing disease-modifying treatments for neurodegenerative diseases highlight the significant market opportunity for successful candidates. The company's efforts to secure additional financing through at-the-market offerings are common for clinical-stage biotechs that have not yet generated revenue, reflecting the capital-intensive nature of drug development. The dismissal of a class action lawsuit, despite an appeal, could be seen as a positive signal regarding the company's legal standing in a sector often prone to litigation.

Comparison to Industry Standards

• The company's continued net losses and reliance on financing activities are typical for clinical-stage biopharmaceutical companies that have not yet brought a product to market and are heavily investing in R&D.
• The EMA's acceptance of the MAA for ANAVEX2-73 for Alzheimer's disease is a significant step, comparable to other companies advancing late-stage candidates, though the outcome remains uncertain given the high bar for Alzheimer's drug approvals (e.g., Biogen's Aduhelm, Eli Lilly's Donanemab, Eisai's Leqembi, which have faced varying degrees of regulatory scrutiny and market adoption).
• The mixed results for the EXCELLENCE trial in Rett syndrome (RSBQ met, CGI-I not met) are not uncommon in complex neurological disorders, where endpoints can be challenging to achieve uniformly. This contrasts with more definitive successes seen in some rare disease drug approvals, but also avoids outright failure.
• The use of at-the-market offerings and existing purchase agreements for capital raises is a standard financing mechanism for public biotechs to manage dilution and access capital flexibly, similar to how many small-to-mid cap biotechs fund their operations.

Corporate Governance

Legal Proceedings

• A shareholder class action complaint filed on March 13, 2024, alleging violations of the Securities and Exchange Act of 1934 related to ANAVEX2-73 clinical trials for Rett syndrome, was dismissed by the US District Court for the Southern District of New York on June 18, 2025. The plaintiff filed a notice of appeal on July 17, 2025.
• A similar complaint filed by Kenneth Downing on May 8, 2024, was voluntarily dismissed by the plaintiff subsequent to the company's motion to dismiss.
• A derivative lawsuit filed on or about May 13, 2024, in the US District Court for the District of Nevada, asserting common law claims and Section 14(a) violations related to Rett syndrome clinical trial disclosures, has been stayed until the motion to dismiss in the initial class action is decided.
• Another derivative lawsuit filed on February 14, 2025, in the Supreme Court for the State of New York, County of New York, asserting state law breach of fiduciary duty and unjust enrichment claims based on similar allegations, has also agreed to a stipulation to stay the proceeding pending the class action lawsuit's motion to dismiss ruling.

Related Party Transactions

• During the nine months ended June 30, 2025, the company issued 217,503 shares of common stock to its Chief Executive Officer upon a net exercise of an option, withholding 47,745 shares for the exercise price and 234,752 shares for tax withholding obligations.

Stakeholder Impact

• **Shareholders**: Increased net loss and cash burn could be a concern, but the new ATM offering provides liquidity while also posing potential for dilution. Progress in clinical trials, especially the EMA MAA acceptance, could positively impact future share value if successful. Ongoing legal proceedings introduce uncertainty and potential costs.
• **Employees**: The increase in share-based compensation charges, particularly from new milestone-based options, could be a positive for employee retention and motivation. The 401(k) plan contributions continue to support employee benefits.
• **Patients/Caregivers**: Continued clinical development of ANAVEX2-73 and ANAVEX3-71 offers hope for new treatments for severe CNS diseases like Alzheimer's, Parkinson's, Rett syndrome, and schizophrenia. The compassionate use program for Rett syndrome patients indicates continued access to treatment.
• **Regulatory Authorities**: The company's engagement with the EMA for MAA submission and the FDA for Fast Track and Orphan Drug designations demonstrates adherence to regulatory pathways, though the unpredictable nature of approvals remains a key factor.

Next Steps

• EMA scientific review and decision-making process for the ANAVEX2-73 MAA for Alzheimer's disease.
• Submission of ANAVEX2-73 Parkinson's disease trial results to regulatory authorities to obtain guidance for further clinical trials.
• Reporting of top-line data for the Phase 2 ANAVEX3-71-SZ-001 clinical trial in schizophrenia in the second half of 2025.
• Potential utilization of the new $150 million Sales Agreement with TD Securities for capital raising.
• Potential filing of a prospectus supplement to access the remaining $110.8 million under the 2023 Purchase Agreement with Lincoln Park Capital.
• Continued evaluation of the impact of the 'One Big Beautiful Bill Act' on financial statements, particularly regarding R&D expenditures for US income tax purposes.

Key Dates

Recommendation

Anavex Life Sciences Corp. presents a mixed bag for investors. While the company is making significant clinical progress, particularly with the EMA submission for ANAVEX2-73 in Alzheimer's and the advancement of ANAVEX3-71 in schizophrenia, these are still clinical-stage assets with uncertain outcomes. The increased net loss and cash burn are concerning, but the company's liquidity position is stated as sufficient for the next 12 months, and the new $150 million ATM facility provides a capital runway. However, this also implies potential future dilution. The ongoing legal challenges, despite recent dismissals, add a layer of risk due to the appeal and pending derivative lawsuits. Given the high-risk, high-reward nature of clinical-stage biopharma, coupled with the current financial trajectory and legal overhang, a 'hold' recommendation is appropriate. Investors should monitor the EMA's decision on ANAVEX2-73, the top-line data for ANAVEX3-71, and the resolution of legal proceedings for clearer catalysts.

Keywords

Biopharmaceutical, Clinical Stage, Neurodegenerative Diseases, Neurodevelopmental Diseases, Alzheimer's Disease, Parkinson's Disease, Rett Syndrome, Schizophrenia, ANAVEX2-73, blarcamesine, ANAVEX3-71, SIGMAR1, Clinical Trials, SEC Filing, 10-Q, Biomarkers, Orphan Drug Designation, Fast Track Designation, EMA MAA, Capital Raise, At-the-Market Offering, Legal Proceedings